Stock Pulse
McKesson (MCK) recently acquired PRISM Vision Holdings for $850 million, expanding into the ophthalmology market and expecting the deal to be accretive to earnings [5], [8]. The company's stock has performed well recently, outperforming the market and its sector [1], [2], [4]. Strong revenue and earnings growth are projected for the next fiscal year, though analysts have slightly lowered estimates [1], [2], [4]. While the stock is considered attractively valued compared to peers, its forward P/E is higher than the industry average [1], [2], [4]. McKesson's CEO sold a significant amount of stock through a pre-arranged plan [10]. Despite a Zacks Rank of 3 (Hold), suggesting performance in line with the market, some analysts are bullish on McKesson's growth potential due to its strong market position and favorable industry trends [1], [2], [6], [7], [9].